Eric Alcera
Child & Adolescent Psychiatry · New York, NYNPI 1912054024
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 66.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $3,651 and has fallen 95.1% since, to $180 in 2025. Among child & adolescent psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- AbbVie$525
- Otsuka America Pharmaceutical, Inc.$346
- Lundbeck LLC$161
- Avanir Pharmaceuticals, Inc.$139
- Indivior Inc.$132
- plus $675 from 12 others
What the payments were for
- Consulting fees$3,00051%
- Travel & lodging$3005%
- Food & beverage$2,51843%
- Education$471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $3,886 |
| AbbVie(2 entities) | 44 | $525 |
| Otsuka America Pharmaceutical, Inc. | 17 | $346 |
| Lundbeck LLC | 10 | $161 |
| Avanir Pharmaceuticals, Inc. | 5 | $139 |
| Indivior Inc. | 9 | $132 |
| Teva Pharmaceuticals USA, Inc. | 8 | $117 |
| Alkermes, Inc. | 7 | $103 |
| Corium, LLC | 6 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $76 |
| Sunovion Pharmaceuticals Inc. | 7 | $74 |
| Tempus AI, Inc | 3 | $71 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $28 |
| Neurocrine Biosciences, Inc. | 2 | $22 |
| Bioxcel Therapeutics, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Validus Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,864 in reported general payments places this provider in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 11 | $172 |
| Risperidone | 13 | $163 |
| Sertraline Hcl | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in New York
- Matthew LorberNew York$398K
- Jeffrey NewcornNew York$165K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Alexander KolevzonNew York$10K
- Moira RynnNew York$8K
- Jeremy Veenstra-VanderweeleNew York$7K
- Adam CohenNew York$3K
- Philip VincentNew York$2K
- Shannon DelaneyNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.